Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Venetoclax con chemioterapia di combinazione nel trattamento di pazienti con leucemia mieloide acuta di nuova diagnosi o recidivante o refrattaria

29 ottobre 2026 aggiornato da: M.D. Anderson Cancer Center

Uno studio di fase 1b/2 sull'inibitore del BCL-2 Venetoclax in combinazione con la terapia intensiva standard di induzione/consolidamento della LMA con FLAG-IDA in pazienti con LMA di nuova diagnosi o recidivante/refrattaria

This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine, cytarabine, filgrastim and idarubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with combination chemotherapy may work better in treating patients with acute myeloid leukemia.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability and to determine the dose-limiting toxicity and the maximum tolerated dose MTD of the combination of fludarabine, cytarabine, filgrastim (GCSF), idarubicin (FLAG-IDA) + venetoclax for patients with acute myeloid leukemia (AML) (Phase 1b).

II. To determine the overall activity of this combination in patients newly diagnosed or relapsed/refractory (AML) (Phase 2).

SECONDARY OBJECTIVES:

I. Determine the preliminary assessment of efficacy by response to revised International Working Group (IWG) criteria and time to response variables including overall survival (OS), event-free survival (EFS) and duration of response (DOR).

II. Determine biomarkers that may be predictive of venetoclax activity.

OUTLINE: This is a phase I, dose-escalation study of venetoclax followed by a phase II study.

INDUCTION THERAPY: Patients receive venetoclax orally (PO) on days 1-14, fludarabine intravenously (IV) over 30 minutes on days 2-6, cytarabine IV over 4 hours on days 2-6, idarubicin IV over 15-30 minutes on days 4 and 5, filgrastim subcutaneously (SC) on days 1-7, or pegfilgrastim SC after day 5. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION THERAPY: Patients receive venetoclax PO on days 1-7, fludarabine IV over 30 minutes on days 2-4, cytarabine IV over 4 hours on days 2-4, filgrastim SC on days 1-7, or pegfilgrastim SC after days 3. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive idarubicin as in Induction Therapy during 1 cycle of Consolidation Therapy per the treating physician.

MAINTENANCE THERAPY: Patients receive venetoclax PO on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up within 30 days.

Tipo di studio

Interventistico

Iscrizione (Stimato)

116

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • M D Anderson Cancer Center
        • Contatto:
        • Investigatore principale:
          • Courtney DiNardo

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator
  • Patients older than 65 who are deemed fit to receive intensive chemotherapy by the treating physician will be eligible after discussion with the principal investigator (PI).
  • Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Creatinine clearance >= 30 mL/min based on the Cockcroft-Gault equation
  • Total bilirubin < 1.5 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement
  • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement
  • Ability to understand and provide signed informed consent
  • Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug
  • Only patients who are relapsed, refractory, or intolerant of standard AML therapy will be eligible for Part 1 (minimum of 1 prior line of AML-directed therapy)

Exclusion Criteria:

  • Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)
  • Patients having received any prior BCL2 inhibitor therapy
  • Subject has known active central nervous system (CNS) involvement with AML
  • Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan
  • Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias
  • Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
  • Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally
  • Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study
  • Subject has a white blood cell count > 25 x 10{9}/L. (Note: hydroxyurea is permitted to meet this criterion)
  • Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (a) appropriate method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (venetoclax, FLAG-IDA)

See detailed description.

Given IV

Altri nomi:
  • .beta.-Citosina arabinoside
  • 1-.beta.-D-Arabinofuranosil-4-ammino-2(1H)pirimidinone
  • 1-.beta.-D-Arabinofuranosilcitosina
  • 1-Beta-D-arabinofuranosil-4-ammino-2(1H)pirimidinone
  • 1-Beta-D-arabinofuranosilcitosina
  • 1.beta.-D-Arabinofuranosilcitosina
  • 2(1H)-pirimidinone, 4-ammino-1-beta-D-arabinofuranosil-
  • 2(1H)-pirimidinone, 4-ammino-1.beta.-D-arabinofuranosil-
  • Alessandro
  • Ara-C
  • Cellula ARA
  • Arabo
  • Arabinofuranosilcitosina
  • Arabinosilcitosina
  • Aracitidina
  • Aracitina
  • Beta-citosina arabinoside
  • CHX-3311
  • Citarabinum
  • Cytarbel
  • Cytosar
  • Citosina Arabinoside
  • Citosina-.beta.-arabinoside
  • Citosina-beta-arabinoside
  • Erpalfa
  • Starasid
  • Tarabina PFS
  • U19920
  • U-19920
  • Udicil
  • WR-28453

Given IV

Altri nomi:
  • 4-Demetossidaunomicina
  • 4-DMDR
  • 4-Demetossidaunorubicina

Given PO

Altri nomi:
  • Venclexta
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclixto

Given SC

Altri nomi:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Fattore stimolante le colonie di granulociti umani metionilici ricombinanti
  • rG-CSF
  • Tevagrastim

Given IV

Altri nomi:
  • Fluradosa

Given SC

Altri nomi:
  • Filgrastim SD-01
  • filgrastim-SD/01
  • Fulfila
  • HSP-130
  • Jinyouli
  • Neulasta
  • Neulastim
  • Pegfilgrastim biosimilare HSP-130
  • Pegfilgrastim Pegcyte biosimilare
  • Pegfilgrastim-jmdb
  • SD-01
  • SD-01 G-CSF a durata sostenuta

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall response rate (ORR)
Lasso di tempo: Up to 6 years

Defined as complete response (CR) + CR with incomplete blood count recovery (CRi) + partial response (PR). Will be estimated along with the 95% credible interval.

Up to 6 years
CR/CRi rate
Lasso di tempo: Up to 6 years

Will be estimated along with the 95% credible interval.

Up to 6 years
Hematologic response
Lasso di tempo: Up to 6 years

Will be estimated along with the 95% credible interval.

Up to 6 years
Duration of response
Lasso di tempo: From the date of initial response, assessed up to 6 years

Defined as the number of days from the date of initial response (PR or better) to the date of first documented disease progression/relapse or death, whichever occurs first. Will be calculated for all patients.

From the date of initial response, assessed up to 6 years
Event-free survival
Lasso di tempo: From the date of treatment initiation, assessed up to 6 years

Defined as the number of days from the date of treatment initiation (i.e., course 1 day 1) to the date of documented treatment failure, relapses from CR, or death from any cause, whichever occurs first. Will be calculated for all patients. Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients.

From the date of treatment initiation, assessed up to 6 years
Overall survival
Lasso di tempo: Up to 6 years

Estimated using Kaplan-Meier method. Log-rank tests will be used to compare among subgroups of patients.

Up to 6 years
Anti-tumor activity
Lasso di tempo: Up to 6 years

Will be summarized graphically and with descriptive statistics.

Up to 6 years
Pharmacodynamic markers
Lasso di tempo: Up to 6 years

Two samples t-test /Wilcoxon rank sum tests will be used to compare pharmacodynamics/pharmacokinetics (PD/PK) parameters between responder and non-responders, and logistic regression analysis will also be used to evaluate the association of PD/PK parameters with response.

Up to 6 years
Drug exposure levels
Lasso di tempo: Up to 6 years

Will be summarized graphically and with descriptive statistics.

Up to 6 years
Overall incidence and severity of all adverse events
Lasso di tempo: Up to 6 years

Graded using Common Toxicity Criteria version 4.0. Safety data will be summarized using frequency and percentage, by category and severity.

Up to 6 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Morphologic leukemia-free state
Lasso di tempo: Up to 6 years

Will be estimated along with the 95% credible interval.

Up to 6 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Exploratory biomarkers
Lasso di tempo: Up to 6 years

Will be summarized graphically and with descriptive statistics. Peripheral blood and bone marrow aspirate samples will be obtained at study specified time points. Biomarker assays may include, but are not limited to, BH3 profiling and characterization of BCL-2 and related proteins, and assessment of the depth of response and monitoring of disease recurrence by assessment of minimal residual disease (MRD) in the bone marrow.

Up to 6 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Courtney DiNardo, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 settembre 2017

Completamento primario (Stimato)

30 settembre 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

10 luglio 2017

Primo inviato che soddisfa i criteri di controllo qualità

10 luglio 2017

Primo Inserito (Effettivo)

11 luglio 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi